Beatrice Knudsen, MD, PhD
About Beatrice Knudsen, MD, PhD
Biomarkers of Response to Treatment with XL184 in the Bone
XL184 (caboxantanib) is a new experimental medication for metastatic prostate cancer with promising clinical results. To more effectively administer XL184 to patients with metastatic prostate cancer, Dr. Knudsen seeks to define the precise anti-cancer mechanism of action. She has assembled a team at Cedars-Sinai in Los Angeles and University of Washington/Fred Hutchinson Cancer Institute in Seattle to study the effects of XL184 in patient biopsies and will investigate the mechanism of action of this encouraging agent as a biomarker for response in patients.
Potential patient benefit: An understanding of the mechanism of action of XL184 will accelerate the clinical development of this very encouraging agent by providing investigators with laboratory and imaging biomarkers of response.
Cedars-Sinai Medical Center